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Abstract
Rationale:Limitations inmethods for the rapiddiagnosisof hospital-
acquired infections often delay initiation of effective antimicrobial
therapy. New diagnostic approaches offer potential clinical and
cost-related improvements in the management of these infections.
Objectives:Wedeveloped a decisionmodeling framework to assess
the potential cost-effectiveness of a rapid biomarker assay to identify
hospital-acquired infection inhigh-riskpatients earlier than standard
diagnostic testing.
Methods:The framework includes parameters representing rates of
infection, rates of delayed appropriate therapy, and impact of delayed
therapy on mortality, along with assumptions about diagnostic test
characteristics and their impact ondelayed therapy and lengthof stay.
Parameter estimates were based on contemporary, published studies
and supplemented with data from a four-site, observational, clinical
study. Extensive sensitivity analyses were performed. The base-case
analysis assumed 17.6% of ventilated patients and 11.2% of
nonventilated patients develop hospital-acquired infection and that
28.7% of patients with hospital-acquired infection experience delays
in appropriate antibiotic therapy with standard care. We assumed
this percentage decreased by 50% (to 14.4%) among patients with
true-positive results and increased by 50% (to 43.1%) among patients
with false-negative results using a hypothetical biomarker assay. Cost
of testing was set at $110/d.
Measurements and Main Results: In the base-case analysis,
among ventilated patients, daily diagnostic testing starting on
admission reduced inpatient mortality from 12.3 to 11.9% and
increased mean costs by $1,640 per patient, resulting in an
incremental cost-effectiveness ratio of $21,389 per life-year saved.
Among nonventilated patients, inpatient mortality decreased from
7.3 to 7.1% and costs increased by $1,381 with diagnostic testing.
The resulting incremental cost-effectiveness ratio was $42,325 per
life-year saved. Threshold analyses revealed the probabilities of
developing hospital-acquired infection in ventilated and
nonventilated patients could be as low as 8.4 and 9.8%,
respectively, to maintain incremental cost-effectiveness ratios
less than $50,000 per life-year saved.
Conclusions:Development and use of serial diagnostic testing that
reduces the proportion of patients with delays in appropriate
antibiotic therapy for hospital-acquired infections could reduce
inpatient mortality. The model presented here offers a cost-
effectiveness framework for future test development.
Keywords: cost-benefit analysis; ventilator-associated
pneumonia; cross infection; early diagnosis
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Infection poses a substantial risk to
hospitalized patients, particularly those in
intensive care units (ICUs). Recent estimates
indicate that 1.7 million hospital-acquired
infections (HAIs) occur annually in U.S.
hospitals, costing $9.8 billion and causing
approximately 100,000 deaths (1).
Hospital-acquired pneumonia (HAP),
including ventilator-associated
pneumonia (VAP), accounts for
approximately 20% of all HAIs; however,
the high mortality rate of 10 to 50%
results in the greatest relative number of
HAI deaths (z36,000 annually) (1, 2).
HAP-associated morbidity is expectedly
high, with extended hospital stays ranging
from 11 to 25 days and an increase in
costs of $10,000 to $49,000 per episode of
VAP (3–5). These costs do not include an
estimate of the broader personal and
societal costs.
The disproportionate HAI-associated
morbidity and mortality will always make
prevention the primary goal. A secondary
goal is early identification and appropriate
treatment, which has repeatedly been shown
to decrease mortality in the setting of severe
sepsis or shock (6–8). However, empiric
antibiotic therapy in the absence of shock
is not necessarily beneficial (9, 10).
Outcomes including mortality improve
when antibiotics are limited to those
patients who actually have infection and for
the shortest duration necessary (9, 10).
These competing interests create a
challenge for providers as they attempt to
identify which patients will benefit and
which might be harmed.
This balance is difficult to accomplish.
Patients rarely declare their infectious
complications with resounding clarity.
Instead, a nonspecific change in clinical
status often triggers a search for infection or
other potential causes. Unfortunately, the
tools necessary to make a precise diagnosis
are inadequate. Currently available
microbiological diagnostic techniques have
limitations including low sensitivity, low
specificity, or lengthy time to result (11). An
improved approach to diagnostic testing is
needed. In particular, a timely and accurate
HAI diagnostic could guide empiric or
tailored therapy while minimizing overuse
or misuse of antimicrobials. This, in turn, is
expected to improve health outcomes,
shorten length of stay (LOS), and reduce
medical costs.
We conducted a prospective
observational cohort study of patients at risk
for HAI to identify novel, host-derived
biomarkers to differentiate patients with
infection from those without. This study
provided data regarding onset of infection,
timing and appropriateness of antimicrobial
therapy, and in-hospital outcomes. As an
adjunct to that study, we sought to develop a
decision-analytic framework that could
be used to evaluate the potential cost-
effectiveness of a diagnostic test that could
shorten the time to identify patients with
HAI and initiate appropriate antibiotic
therapy compared with standard diagnostic
procedures.
Methods
Prospective Cohort Study
Enrollment in this prospective, multicenter,
observational cohort study targeted
hospitalized patients 18 years of age or
older at Duke University Medical Center,
Duke Regional Hospital, Durham Veterans
Affairs Medical Center, and the University
of North Carolina-Chapel Hill Hospital. The
purpose of this prospective cohort study
was to understand the clinical andmolecular
risk factors for HAI and their temporal
dynamics. Each hospital’s institutional
review board for human studies approved
the protocols, and written consent was
obtained from the subjects or their
surrogates.
HAI included surgical site infection
(12), central line–associated bloodstream
infection (13), catheter-associated urinary
tract infection (14), Clostridium difficile–
associated diarrhea (15), HAP (16), and
VAP (16). Participants were enrolled if
they developed suspected HAI or were at
risk for HAI by virtue of intubation
(without active infection at the time of
enrollment and expected duration of
intubation. 2 d). Biological, demographic,
laboratory, and clinical data were collected
for up to 14 days. Follow-up assessments,
including survival and discharge
disposition, occurred 14 and 30 days after
onset of infection.
Model Structure
A deterministic decision-analytic model was
designed to estimate costs representing the
health system perspective and survival in
hospitalized patients at high-risk for HAI.
Model estimates were derived from our
prospective cohort study or from published
medical literature, as detailed below.
The decision tree shown in Figure 1
represents the choice between a standard
diagnostic evaluation and one augmented
by a novel HAI diagnostic test (referred to
as “biomarker assay”). The nature of the
assay is unspecified, to imply that any
number of diagnostic modalities can be
represented in this decision-analytic model.
Hospitalized patients requiring
mechanical ventilation bear a higher risk
of infection than nonventilated patients.
Moreover, these ventilated patients are
frequently sedated, limiting their ability to
communicate symptoms suggestive of a
new infection. We therefore analyzed the
impact of a hypothetical diagnostic assay
separately for ventilated and nonventilated
patients. Patients who are ventilated are
at risk of developing VAP or non-VAP
HAI. The structure was the same for
nonventilated patients except that they are
not at risk of developing VAP.
Conditional on infection, patients were
then grouped according to the probability
that they received timely or delayed
appropriate antimicrobial therapy.
We incorporated hypothetical test
characteristics (i.e., sensitivity and
specificity) for the biomarker assay strategy
by modeling true positives and false
negatives among those with infection and
true negatives and false positives among
those without an infection. The modeled
benefit from biomarker assay testing is a
reduction in the probability that patients
with infection receive delayed appropriate
antimicrobial therapy. Patients in all groups
are at risk of all-cause in-hospital mortality.
However, patients receiving delayed
antimicrobial therapy experience a higher
risk of in-hospital mortality.
Model Inputs
Table 1 summarizes the model parameters
and their corresponding values applied
in the base-case analysis and the values
tested in sensitivity analysis. Probabilities
corresponding to the development of
various types of infections were derived
using the midpoint (10%) of the rates of
VAP among ventilated patients recently
reported by Klompas and colleagues (17)
along with North American data reported
from the large Extended Prevalence of
Infection in Intensive Care (EPIC II) study
(18). Estimates of the probability of
receiving delayed antibiotic treatment with
standard care (28.7%) and the increased
risk of mortality with delayed versus timely
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therapy (odds ratio, 3.4) were based on a
large U.S.-based cohort study by Vazquez-
Guillamet and colleagues (19). In sensitivity
analyses, probability of delayed therapy
varied from 19.9 (20) to 69.0% (21), and the
odds ratio for mortality resulting from
delayed appropriate therapy varied from
2.23 (22) to 7.68 (6).
Risk estimates in the literature
represent a mixture of patients with timely
and delayed antibiotic therapy.We therefore
computed probabilities of death with timely
therapy by incorporating the increased odds
of death with delayed therapy and the
overall risk of death in all patients with a
given type of infection. Then, we computed
the probability of death with delayed
therapy by multiplying the relative risk of
mortality (converted from the odds ratio)
with delayed therapy by the probability of
death in patients receiving timely treatment.
For instance, Rosenthal and colleagues
reported that 25% of patients died with VAP
(23). Combining estimates reported by
Vazquez-Guillamet and colleagues (19) and
Rosenthal and colleagues (23), we
calculated the probability of death as 18%
in ventilated patients with VAP receiving
timely treatment and 43% in patients
receiving delayed treatment. The relative
risk of ventilation status on mortality
derived from Vincent and colleagues
(18) was used to compute a 9% mortality
rate with timely treatment and a 26%
mortality rate with delayed treatment for
nonventilated patients with HAI.
To compute life-years saved, we applied
estimated years of remaining life expectancy
from the National Center for Health
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Figure 1. Decision tree for ventilated patients. HAI = hospital-acquired infection; VAP = ventilator-associated pneumonia.
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Statistics for patients of all races and both
sexes, conditional on age at hospitalization
(24).
Unit costs were limited to the daily cost
per day in the hospital and the daily cost of
the biomarker assay. The daily cost of
inpatient care was estimated at $3,308 based
on a recent metaanalysis of costs associated
with health care–acquired infections (25).
Daily inpatient costs were varied from
$996 (26) to $7,243 (25) per day in
sensitivity analyses. These daily cost
estimates were applied to LOS estimates
measured in the observational cohort study
described above. In the base-case analysis,
we set the cost of the biomarker assay at
$110 per day. This was based on costs for
existing sepsis-related diagnostics. For
example, the cost of matrix-assisted laser
desorption/ionization time-of-flight
(MALDI-TOF) was estimated to be $15/test
at our institution, after accounting for
capital equipment, installation, annual
contracting, technician time, and
consumables. We also considered
procalcitonin, for which the Centers for
Medicare and Medicaid Services
reimbursed $36.45 in 2015 (27). Finally,
peptide nucleic acid fluorescence in situ
hybridization (PNA-FISH) costs were
derived from Alexander and colleagues
(28). After adjusting to 2015 dollars, this
yielded an assay cost of $110. Sensitivity
analysis used a range of $15 to $200.
All medical costs included in the model
are incurred over a relatively short time
period. Therefore, we did not apply a
discount rate to costs. For estimated
survival, we applied the recommended
discount rate of 3% per year (29).
Hypothetical patients represented in our
base-case analyses were assumed to be
60 years old.
Base-Case Analysis
We performed two sets of base-case
analyses: one for ventilated patients and one
for nonventilated patients. In both sets of
analyses, we assumed that testing with the
biomarker assay was initiated on the day of
admission and continued until patients
developed an infection, died, or were
discharged. For the biomarker assay testing
strategy, we assumed that test sensitivity and
specificity were both 0.9 with daily
monitoring, a performance threshold
considered high enough to impact medical
decision making. We assumed that a
positive assay would reduce the probability
of receiving delayed treatment by 50%.
In the case of true positives, the
mortality benefit resulting from fewer
patients receiving delayed therapy was
applied. However, for false positives, the
baseline risk of mortality in individuals
without infection was applied; but, we
assumed that patients would receive
unnecessary therapy and testing that would
extend the hospital stay by 2 days and would
also increase mortality by 0.2 percentage
points. In cases where daily assays were
negative for an individual with an infection
(i.e., false negatives), we assumed a 50%
increase in the probability of receiving
delayed therapy versus usual care and
imposed a 3-day extension to hospital stay
and 1 percentage point increased risk of
in-hospital death (as a result of
delayed therapy).
Sensitivity and Threshold Analyses
Sensitivity analyses were conducted to
reflect uncertainty across model inputs that
were believed to be influential on the results.
Specifically, we varied sensitivity and
specificity of the diagnostic testing strategy,
probability of developing HAI, probability
of receiving delayed treatment, percentage
reduction in delayed treatment versus
usual care with true-positive results and
percentage increase in delayed therapy
with false-negative results with testing,
negative consequences of false-positive
and false-negative tests on mortality and
LOS, probability of in-hospital mortality in
patients with infection, relative risk of
in-hospital mortality with delayed antibiotic
therapy, additional days of hospitalization
for those receiving delayed treatment,
cost per inpatient day, the daily cost of
diagnostic testing, LOS, and patient age. We
also performed threshold analyses to
determine the minimum or maximum
values for model inputs that would result in
an incremental cost-effectiveness ratio equal
to $50,000 per life-year saved.
Results
Clinical Population
A total of 219 patients hospitalized at Duke
University Hospital, Duke Regional
Hospital, Durham Veterans Affairs Medical
Center, or the University of North Carolina
Health Care system were enrolled in this
prospective study between 2011 and 2012.
Because this was an observational study, no
treatment or intervention was used.
Mean age was 58.5 years (range, 19–87
yr), 69% of patients were men, 162 were
white (74%), and 52 were black (24%).
Thirty-day mortality from the time of
enrollment was 16.0% (35/219), with a
median of 5 (interquartile range, 2.5–12)
days to death. Of the 219 enrolled patients,
90 (41%) had infection at the time of
enrollment, 29 (13%) developed infection
after enrollment, 53 (24%) had no infection
during the observation period, and 47
(21%) subjects had illness that was
inconclusive for infection. Eighty-eight
patients were intubated but without
infection at the time of enrollment. Of this
group, 33 (38%) remained uninfected,
24 (27%) developed infection within 1
week, 1 developed infection after more than
1 week, and 30 (34%) had complications
that were indeterminate for infection.
Among ventilated patients, in-hospital
mortality was 19.2% among those who
developed VAP, 7.7% among those who
developed other non-VAP HAI, and 18.2%
among ventilated patients who did not
develop an infection.
In light of the highly selected nature of
this cohort, it was only used to define days to
discharge, intubation, infection diagnosis,
and appropriate antimicrobial therapy as
measured in ventilated/uninfected patients,
ventilated patients with subsequent HAI, and
nonventilated patients with subsequent HAI.
Ventilated Patients
The proportion of ventilated patients (with
or without infection) who received delayed
antibiotic therapy decreased from to 5.1
to 3.0% as a result of earlier diagnosis due
to testing. When accounting for the $110
daily test cost beginning on the day of
admission, total inpatient costs per patient
were $58,235 in the biomarker assay group
and $56,595 in the standard care group,
representing a $1,640 increase (Table 2). In
terms of health outcomes, the biomarker
assay strategy among ventilated patients
was estimated to reduce inpatient mortality
from 11.88 to 12.33%, leading to a gain in
life-years saved of 0.08 per patient. When
combining the estimated increase in costs
with gains in life expectancy, the resulting
cost-effectiveness ratio was $21,389 per
life-year saved. Results were similar when
we assumed that diagnostic testing would
begin on the date of intubation, with an
estimated net cost increase of $1,537 and an
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incremental cost-effectiveness ratio of
$20,050 per life-year saved.
Nonventilated Patients
Nonventilated patients were analyzed
separately owing to their lower risk of HAI,
specifically VAP, and lower overall mortality
than ventilated patients. Among patients
who were not ventilated, the biomarker
assay strategy decreased the percentage of
patients receiving delayed antibiotic therapy
from 3.2 to 1.9%. At $110 per day for testing
(base-case estimate), total inpatient costs
were $1,381 higher in the diagnostic testing
group at $31,512 compared with $30,131
in the standard care group. Inpatient
mortality was lower with the diagnostic
testing strategy at 7.13% compared with
7.32% with standard care. With an
estimated gain of 0.03 life-years per patient,
the resulting incremental cost-effectiveness
ratio was $42,325 per life-year saved.
Sensitivity Analyses
The findings from the model were
consistent when varying the sources used for
several model inputs. Increasing the age of
the hypothetical cohort from 60 years to
80 years to demonstrate the impact of
shorter expected survival postdischarge
increased the magnitude of the incremental
cost-effectiveness ratios by 65% (Figures 2
and 3). Assuming that ICU survivors have a
higher mortality than age- and sex-matched
control subjects in the general population
(30–33), we modeled the effect of an 8-year
life expectancy instead of the base-case 16.9
years. This increased the incremental cost-
effectiveness ratio from $21,389 to $45,284
for the ventilated group and from $42,325
to $89,608 for the nonventilated group.
Halving the baseline probabilities of
in-hospital death across infection types
nearly doubled the magnitude of the
incremental cost-effectiveness ratios among
the ventilated and nonventilated analyses.
The base-case scenario assumed an
odds ratio of 3.4 for mortality due to delayed
appropriate antimicrobial therapy (19).
Replacing this with an odds ratio of 2.23
based on Inchai and colleagues (22)
increased the incremental cost-effectiveness
ratio by about 40% to $34,100 per life-year
saved for ventilated patients and $72,192
per life-year saved for nonventilated
patients (Figures 2 and 3). The odds ratio of
in-hospital mortality with delayed antibiotic
therapy could be as low as 1.8 in ventilated
and 2.9 in nonventilated patients to maintain
incremental cost-effectiveness ratios less
than $50,000 per life-year saved. Varying the
probability of HAI among ventilated and
nonventilated patients had greater impact on
the incremental cost-effectiveness ratios
when the probabilities of HAI were
lower (Figure 4). Threshold analyses revealed
that among ventilated patients, the
probability of developing HAI could be as
low as 8.4% and still maintain an incremental
cost-effectiveness ratio less than $50,000 per
life-year saved. The risk of developing an
HAI among nonventilated hospitalized
patients is generally lower than in ventilated
patients, as is the risk of mortality.
Threshold analyses revealed that the
risk of HAI in nonventilated patients could
be as low as 9.8% tomaintain an incremental
cost-effectiveness ratio of less than $50,000
per life-year saved. Threshold analyses also
revealed that the probability of receiving
delayed treatment (28.7% in base-case)
could be as low as 13% for ventilated
patients and 24% for nonventilated patients,
while incremental cost-effectiveness ratios
remained lower than $50,000 per life-year
saved. Varying assumptions that impacted
LOS or cost per day had relatively little
impact on the magnitude of the incremental
cost-effectiveness ratios. The incremental
cost-effectiveness ratios changed very little
when varying the LOS extension for patients
with delayed therapy to 0 days or 4 days
(2 d in the base-case) (Figures 2 and 3).
Varying the cost per inpatient day also had
relatively minor effects on the incremental
cost-effectiveness ratios. Applying a lower
cost published by Kahn and colleagues (26)
representing the marginal cost per day in
the ICU ($996 in 2015), rather than the
average daily cost, was found to reduce
the magnitude of the incremental cost-
effectiveness ratios due to the assumption
that false-positive findings would lead to
longer hospital stays with biomarker assay
testing.
In the base-case analysis, for patients
who develop HAI and have a positive
biomarker assay (i.e., true positives), we
assumed that daily biomarker testing would
reduce the risk of delayed therapy by 50%
(from 28.7 to 14.4%). Limiting the impact
to a 20% reduction had major impact,
increasing the incremental cost-
effectiveness ratio to $78,048 per life-year
saved for ventilated patients and $179,333
per life-year saved for nonventilated
patients. For patients who have HAI but
diagnostic testing fails to detect the infection
(false negative), we assumed diagnostic
testing would result in a 50% increase in the
probability of delayed antibiotic therapy
(i.e., from 28.7 to 43.1%) in the base-case
analysis. When increasing the effect to an
80% increase, the incremental cost-
effectiveness ratio increased slightly to
$23,308 per life-year saved for ventilated
patients and $45,917 per life-year saved for
nonventilated patients.
The base-case analysis also modeled
negative effects of false-positive tests
resulting from unnecessary use of antibiotic
therapy in patients without infection. This
included a 2-day increase in LOS and
additional deaths in 2 out of 1,000 patients.
If false-positive test results increased LOS
by 4 days and increased mortality to 10 in
1,000 patients, the incremental cost-
effectiveness ratios increase by about 50%
for ventilated patients ($32,522) and more
Table 2. Base-case results
With Serial Diagnostic
Testing
Standard Care Difference
Ventilated patients
Length of stay 17.19 17.11 0.08
Total costs, $ 58,235 56,595 1,640
Inpatient mortality, % 11.88 12.33 20.45
Life-years (discounted) 14.92 14.85 0.08
ICER $21,389 per life-year saved
Nonventilated patients
Length of stay 9.28 9.11 0.18
Total costs, $ 31,512 30,131 1,381
Inpatient mortality, % 7.13 7.32 20.19
Life-years (discounted) 15.73 15.70 0.03
ICER $42,325 per life-year saved
Definition of abbreviation: ICER = incremental cost-effectiveness ratio.
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Assign median LOS estimates from cohort study (from mean 
estimates)
Vary percentage increase in delayed treatment with testing 
for false negatives from 20% to 80% (from 50%)
Vary LOS increase with delayed therapy from 0 days to 4 days 
(from 2 days)
Remove negative effects of false-negative tests (from 3-day 
increase in LOS; 1%-point increase in mortality)
Increase negative effects of false-negative tests: 6-day increase in 
LOS; 5%-point increase in mortality (from 2-day increase in LOS; 
0.2%-point increase in mortality)
Vary cost per inpatient day to from $996 to $7243 (from $3308)
Remove negative effects of false-positive tests (from 2-day 
increase in LOS; 0.2%-point increase in mortality)
Decrease baseline risk of mortaliy with VAP to 10% (from 25%)
Increase negative effects of false-positive tests: 4-day increase 
in LOS; 1%-point increase in mortality (from 2-day increase in LOS; 
0.2%-point increase in mortality)
Vary probability of delayed treatment from 69.0% to 19.9% 
(from 28.7%)
Vary odds ratio for death with delayed treatment from 7.68 to 
2.23 (from 3.40)
Increase age of at-risk cohort to 80 years (from 60)
Years of remaining life expectancy reduced to 8 years (from 16.9 
years)
Vary probability of HAI from 26.4% to 8.8% (from 17.6%)
Vary percentage reduction in delayed treatment with testing for true 
positives from 80% to 20% (from 50%)
$0 $10,000 $20,000 $30,000 $40,000
$/QALY.
$50,000 $60,000 $70,000 $80,000
Figure 2. Tornado diagram representing results from sensitivity analysis: ventilated patients. The vertical line represents the incremental cost-
effectiveness ratio (ICER) calculated in the base-case analysis, and the horizontal lines represent difference in ICERs between the base-case analysis and
the sensitivity analysis. The lines on the right side of the vertical lines represent increases in ICERs when compared with the base-case ICER, and the
lines on the left side represent decreases in ICERs when compared with the base-case ICER. HAI = hospital-acquired infection; LOS = length of stay;
QALY = quality-adjusted life year; VAP = ventilator-associated pneumonia.
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Assign median LOS estimates from cohort study (from mean 
estimates)
Vary LOS increase with delayed therapy from 0 days to 4 days (from
2 days)
Vary percentage increase in delayed treatment with testing for false
negatives from 20% to 80% (from 50%)
Remove negative effects of false-negative tests (from 3-day 
increase in LOS; 1%-point increase in mortality)
Increase negative effects of false-negative tests: 6-day increase in 
LOS; 5%-point increase in mortality (from 2-day increase in LOS; 
0.2%-point increase in mortality)
Increase negative effects of false-positive tests: 4-day increase in 
LOS; 1%-point increase in mortality (from 2-day increase in LOS; 
0.2%-point increase in mortality)
Vary cost per inpatient day to from $996 to $7243 (from $3308)
Remove negative effects of false-positive tests (from 2-day 
increase in LOS; 0.2%-point increase in mortality)
Vary probability of delayed treatment from 69.0% to 19.9% (from
28.7%)
Vary odds ratio for death with delayed treatment from 7.68 to 2.23
(from 3.40)
Increase age of at-risk cohort to 80 years (from 60)
Vary probability of HAI from 26.4% to 8.8% (from 11.2%)
Years of remaining life expectancy reduced to 8 years (from 16.9
years)
Vary percentage reduction in delayed treatment with testing for true 
positives from 80% to 20% (from 50%)
$0 $20,000 $40,000
$/QALY .
$60,000 $100,000$80,000
Figure 3. Tornado diagram representing results from sensitivity analysis: nonventilated patients. The vertical line represents the incremental cost-
effectiveness ratio (ICER) calculated in the base-case analysis and the horizontal lines represent difference in ICER between the base-case analysis and
the sensitivity analysis. The lines on the right side of the vertical lines represent increases in ICERs when compared with the base-case ICER and the
lines on the left side represent decreases in ICERs when compared with the base-case ICER. HAI = hospital-acquired infection; LOS = length of stay;
QALY = quality-adjusted life year.
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than doubled for nonventilated patients
($95,569). However, assuming that
false-negative results increased LOS by
6 days and increased mortality to 50
out of 1,000 patients had a relatively small
effect on the incremental cost-effectiveness
ratios ($25,365 for ventilated patients
and $50,965 for nonventilated patients).
If the negative consequences of both
false-positives and false-negatives are
removed, the incremental cost-effectiveness
ratios decrease to $11,844 for ventilated
patients and $18,612 for nonventilated
patients.
Sensitivity analysis related to the cost of
diagnostic testing revealed that the
incremental cost-effectiveness ratios were
a linear function of daily testing cost
(Figure 5). For each $10 increase in the
daily cost, the incremental cost-
effectiveness ratio increased by $1,616
in ventilated patients and $2,227 in
nonventilated patients (Figure 3). The daily
cost of monitoring could be as high as $287
for ventilated patients and $144 for
nonventilated patients to maintain the
incremental cost-effectiveness ratios at less
than $50,000 per life-year saved.
Varying the sensitivity of the biomarker
assay strategy had a greater impact on
the magnitude of the incremental cost-
effectiveness ratios than varying the
specificity (Figure 6). When the test
sensitivity and specificity were decreased to
80% (90% in base-case), the incremental
cost-effectiveness ratio increased to $37,760
per life-year saved for ventilated patients
and $103,698 for nonventilated patients. If
specificity was 90%, test sensitivity could be
as low as 73% for ventilated patients and
86% for nonventilated patients before the
incremental cost-effectiveness ratio
surpassed $50,000 per life-year saved.
Discussion
For the general population, HAIs present a
small and often intangible risk to health.
However, once hospitalized, the risk of
acquiring an infection becomes very
tangible, with a considerable impact on
mortality, morbidity, and costs to the
patient, the hospital, and the public.
Infection-control measures will reduce but
not eliminate the risk of acquiring an
HAI. Moreover, the treatment of such
infections has its own associated challenges.
Delaying appropriate antimicrobial
treatment clearly increases mortality. Yet
the use of broad-spectrum antimicrobials
when there may not actually be an infection
also exposes the patient to risk.
The diagnostic tools guiding clinicians
in this delicate balance are inadequate. As a
result, there has been renewed interest in
novel diagnostic techniques. Specifically, a
diagnostic test offering a timely and accurate
identification of incipient infection could
speed the provision of appropriate therapy
and avoid unnecessary antibiotic treatment,
which will reduce subsequent costs in
terms of antimicrobial resistance and
medical expenditures. Another diagnostic
strategy is one that quickly identifies
resistant organisms so that appropriate
antibiotic treatment can be started sooner.
Indeed, there are many possible strategies to
improve on the state of sepsis diagnosis.
Through the use of economic modeling
based on published and acquired data, we
identify the parameters that are most
influential to determining the cost-
effectiveness of a putative diagnostic assay.
Even though such diagnostics have yet to be
developed and their clinical utility is
hypothetical, the development and
publication of a transparent economic
modeling framework, agnostic about the
diagnostic strategy, can prospectively
address stakeholders’ concerns about
potential bias and can be applied to
institution-specific infection rates, costs,
and other inputs to aid in adoption
decisions.
Results from our model reveal that a
diagnostic with high sensitivity and
specificity that leads to an absolute
reduction from 5.1 to 3.0% (40% relative
reduction) in the proportion of patients
receiving delayed antibiotic therapy, testing
at $110 per day, represents an efficient care-
management strategy with cost-
effectiveness ratios of about $21,000 per
life-year saved in ventilated patients and
$42,000 in nonventilated patients.
Sensitivity analyses revealed that large
changes to most of the model’s parameters
would be necessary to generate incremental
cost-effectiveness ratios that surpass
$50,000 per life-year saved. The risk of HAI
can vary significantly across patients’
clinical characteristics and institutions.
However, we found that a diagnostic test
could be cost effective at the $50,000 per
life-year saved threshold in ventilated
patients with a risk of acquiring an HAI as
low as 8.4% if the daily cost of testing is
$110 or as low as 14.2% even if the daily
cost of testing doubled to $220. We
recognize, however, that an ideal diagnostic
would lead not only to improved survival
but also to reduced costs.
In our model, cost savings were entirely
attributable to reductions in the LOS
among patients who received earlier
appropriate antimicrobial therapy because
of testing. We did not assign longer (or
shorter) stays for patients who died as a
result of infection, but we applied a 2-day
penalty for inappropriate treatment after a
false-positive test result and a 3-day penalty
for prolonged treatment after a false-
negative test result.
With these conservative assumptions,
inpatient costs were lower by just $277 per
ventilated patient and $582 per
nonventilated patient with the diagnostic
testing strategy versus usual care. Although
these savings may seem relatively small from
a budgetary perspective in comparison to
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Figure 4. Impact of varying baseline probability of hospital-acquired infection (HAI) on incremental
cost-effectiveness ratios (ICERs). LYS = life-year saved.
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testing costs of $1,363 per ventilated patient
and $799 per nonventilated patient, the
relative value of testing is largely driven by
the expected (absolute) reductions in
inpatient mortality of 0.45 and 0.19% for
ventilated and nonventilated patients,
respectively. When accounting for these
improvements in mortality, we found that
costs of testing could increase to nearly $300
per day and maintain incremental cost-
effectiveness ratios at $50,000 per life-year
saved for ventilated patients. This cost is well
above estimates for many currently available
tests.
Most economic studies of HAI or
sepsis focus on prevention or treatment
interventions. Fewer describe the cost-
effectiveness of diagnostic strategies, and
those that do focus on a specific strategy to
identify the causative organism in patients
who have already demonstrated signs or
symptoms of infection, such as polymerase
chain reaction in patients with positive
blood cultures (34) or a combination of IL-8
and C-reactive protein in neonates on first
suspicion of a nosocomial bacterial
infection (35). Despite these disparate
diagnostic approaches, they show that more
accurate and timely diagnostics are cost
effective (with incremental cost-
effectiveness ratio of €3,107/quality-
adjusted life years) and at times are cost
saving. The analysis presented here is
consistent with those findings but differs in
that it examines a screening diagnostic used
in all patients at high risk for HAI before
infection is confirmed by other means.
One particular strategy for the
development of novel diagnostic tools is to
target the host response in a more agnostic
manner. Until now, most sepsis diagnostic
studies focus on pathogen detection or on
candidate host markers defined a priori.
Though important, these strategies have
limitations. Recent advances in systems
biology and computational biology have
created new opportunities. For example,
gene-expression analysis has been used to
differentiate active pulmonary tuberculosis
from both latent tuberculosis and
nontuberculous disease (36–38). Test
characteristics were superior to currently
available pathogen-detection techniques.
More recently, host gene-expression
signatures were identified that
discriminated community-acquired
pneumonia versus noninfectious disease on
admission to the ICU (39). However,
these strategies were applied to patients in
whom clinical disease was well established.
Instead, a more effective diagnostic
would detect early disease, when clinical
symptoms might be mild and when
treatment would be most effective.
Examples include viral respiratory infection
(40), VAP (41, 42), post-trauma infection
(43), and sepsis (44, 45). Although none of
these particular gene-expression signatures
has advanced to clinical use, they exemplify
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new diagnostic strategies that can change
how infection is diagnosed and
subsequently managed (46).
Limitations
There are several limitations associated
with the current study. First, the use of a
model is a simplification of reality, requiring
assumptions and an assembly of inputs from
many sources. However, each of the model’s
assumptions and inputs are explicitly
documented, and we conducted numerous
sensitivity analyses to examine the impact
of using alternative values for parameter
estimates.
Despite reliance on numerous sources,
the specific estimates required for the model
were sometimes not available in the
published medical literature. We also did
not conduct probabilistic sensitivity
analyses using Monte Carlo simulations that
would allow values for each of the model
parameters to vary simultaneously
according to distributions assigned to
represent their uncertainty. Given the need
to rely on nonsampled estimates and
assumptions (e.g., daily cost and impact of
diagnostic testing, sensitivity and specificity
of testing, impact of test results on receipt
of delayed vs. timely therapy), we believed
that artificially assigning distributions to
these variables could obfuscate the
exploratory nature of the modeling
framework. Moreover, VAP is exceedingly
difficult to accurately diagnose and is known
to have high interobserver variability (47,
48). Consequently, the National Healthcare
Safety Network has replaced VAP with
VAE (ventilator-associated events) for
surveillance purposes. However, this
change does not eliminate the existence of
VAP and underscores why a diagnostic,
such as the type relevant to our modeling
framework, would be of potential value.
Conclusions
A diagnostic biomarker that shortens the
time to identify HAI in an at-risk population
is cost effective under various conditions
and cost parameters. The model presented
here offers a decision-analytics framework
with which the potential cost-effectiveness
of new biomarkers can be evaluated. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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